The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats

Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239.

Abstract

The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 months with GC (methylprednisolone) 9 mg/kg/day or GHS (Ipamorelin) 100 microg/kg three times daily, or both GC and GHS in combination. The maximum tetanic tension of the calf muscles was determined in vivo in a materials testing machine. The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with GC and GHS in combination, compared with the group injected with GC alone. In conclusion, the decrease in muscle strength and bone formation found in GC-injected rats was counteracted by simultaneous administration of the growth hormone secretagogue.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Development / drug effects*
  • Bone Development / physiology
  • Female
  • Glucocorticoids / antagonists & inhibitors
  • Glucocorticoids / pharmacology*
  • Hormones / pharmacology*
  • Methylprednisolone / pharmacology*
  • Muscle Contraction / drug effects
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / physiology*
  • Oligopeptides / pharmacology*
  • Rats
  • Rats, Wistar

Substances

  • Glucocorticoids
  • Hormones
  • Oligopeptides
  • Methylprednisolone
  • ipamorelin